BLRX 6-K: Divestiture
BioLineRx
Filed with the SEC on · accession 0001178913-26-005266
BLRX filed a 6-K (foreign company report) with the SEC on Nov 18, 2026. BioLineRx entered into a Purchase and Sale Agreement with SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, to sell 80% of its future royalty payments on net sales of APHEXDA (motixafortide) under its license agreement with Ayrmid Pharma for a one-time purchase price of…
Summary of the filing
BioLineRx entered into a Purchase and Sale Agreement with SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, to sell 80% of its future royalty payments on net sales of APHEXDA (motixafortide) under its license agreement with Ayrmid Pharma for a one-time purchase price of $5.6 million. The company will retain 20% of the royalties and use proceeds to support R&D, including GLIX1 clinical development, and to partially prepay $3.0 million of its loan with Kreos Capital.
Key details
✦ Ask GOAX AI about this filing — what it means for BLRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BLRX?
Click hereFrequently asked questions
What did BLRX file with the SEC on Nov 18, 2026?
BLRX filed a 6-K (Divestiture). BioLineRx entered into a Purchase and Sale Agreement with SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, to sell 80% of its future royalty payments on net sales of APHEXDA (motixafortide) under its license agreement with Ayrmid Pharma for a one-time purchase price of $5.6 million. The company will retain 20% of the royalties and use proceeds to support R&D, including GLIX1 clinical development, and to partially prepay $3.0 million of its loan with Kreos Capital.
What does a divestiture mean for BLRX stock?
A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.
How do I read a 6-K?
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
Other BLRX SEC filings
- SCHEDULE 13G · SEC filingNov 16, 2026
- 6-K · SEC filingNov 16, 2026
- 6-K · SEC filingOct 23, 2026
- 424B3 · Secondary offeringOct 2, 2026
- 6-K · SEC filingSep 24, 2026
- 6-K · Fda approvalSep 10, 2026
- 6-K · SEC filingAug 31, 2026
- 424B5 · Secondary offeringAug 31, 2026
- 6-K · Secondary offeringAug 31, 2026
- 6-K · Secondary offeringAug 28, 2026
Get alerts when BLRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days